These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 33507250)

  • 1. Effectiveness of the 7- and 13-Valent Pneumococcal Conjugate Vaccines Against Vaccine-Serotype Otitis Media.
    Dagan R; Van Der Beek BA; Ben-Shimol S; Pilishvili T; Givon-Lavi N
    Clin Infect Dis; 2021 Aug; 73(4):650-658. PubMed ID: 33507250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Near-elimination of otitis media caused by 13-valent pneumococcal conjugate vaccine (PCV) serotypes in southern Israel shortly after sequential introduction of 7-valent/13-valent PCV.
    Ben-Shimol S; Givon-Lavi N; Leibovitz E; Raiz S; Greenberg D; Dagan R
    Clin Infect Dis; 2014 Dec; 59(12):1724-32. PubMed ID: 25159581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicted serotype-specific effectiveness of pneumococcal conjugate vaccines V114 and PCV20 against invasive pneumococcal disease in children.
    Ryman J; Sachs JR; Yee KL; Banniettis N; Weaver J; Weiss T
    Expert Rev Vaccines; 2024; 23(1):60-68. PubMed ID: 38073483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of 13-valent pneumococcal conjugate vaccination for protection against acute otitis media caused by Streptococcus pneumoniae in healthy young children: a prospective observational study.
    Pichichero M; Kaur R; Scott DA; Gruber WC; Trammel J; Almudevar A; Center KJ
    Lancet Child Adolesc Health; 2018 Aug; 2(8):561-568. PubMed ID: 30119715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: The indirect cohort design, 2006-2018.
    Andrews N; Kent A; Amin-Chowdhury Z; Sheppard C; Fry N; Ramsay M; Ladhani SN
    Vaccine; 2019 Jul; 37(32):4491-4498. PubMed ID: 31272872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pan-serotype Reduction in Progression of Streptococcus pneumoniae to Otitis Media After Rollout of Pneumococcal Conjugate Vaccines.
    Lewnard JA; Givon-Lavi N; Weinberger DM; Lipsitch M; Dagan R
    Clin Infect Dis; 2017 Nov; 65(11):1853-1861. PubMed ID: 29020218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Widespread Introduction of Pneumococcal Conjugate Vaccines on Pneumococcal and Nonpneumococcal Otitis Media.
    Ben-Shimol S; Givon-Lavi N; Leibovitz E; Raiz S; Greenberg D; Dagan R
    Clin Infect Dis; 2016 Sep; 63(5):611-8. PubMed ID: 27225239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of 13-valent pneumococcal conjugate vaccine against vaccine-serotype community acquired pneumococcal diseases among children in China: A test-negative case-control study.
    Xiaofei L; Yudan LI; Qinghui C; Jiaming S; Benfeng Z; Youyi Z; Biying W; Lijun Y; Jun Z; Jianmei T; Lin L; Xuejun S; Genming Z; Tao Z
    Vaccine; 2024 Feb; 42(6):1275-1282. PubMed ID: 38296700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccine effectiveness of the 7-valent and 13-valent pneumococcal conjugate vaccines in Canada: An IMPACT study.
    Ricketson LJ; Bettinger JA; Sadarangani M; Halperin SA; Kellner JD;
    Vaccine; 2022 Apr; 40(19):2733-2740. PubMed ID: 35351324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Substantial reduction of antibiotic-non-susceptible pneumococcal otitis media following PCV7/PCV13 sequential introduction.
    Ben-Shimol S; Givon-Lavi N; Greenberg D; van der Beek BA; Leibovitz E; Dagan R
    J Antimicrob Chemother; 2020 Oct; 75(10):3038-3045. PubMed ID: 32946586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-specific Effectiveness of 7- and 13-Valent Pneumococcal Conjugate Vaccines Against Vaccine-serotype Streptococcus pneumoniae Colonization in Children.
    Lewnard JA; Givon-Lavi N; Dagan R
    Clin Infect Dis; 2020 Nov; 71(8):e289-e300. PubMed ID: 31784753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of pneumococcal conjugate vaccines on healthcare utilization and direct costs for otitis media in children ≤2 years of age in two Swedish regions.
    Edmondson-Jones M; Dibbern T; Hultberg M; Anell B; Medin E; Feng Y; Talarico C
    Hum Vaccin Immunother; 2022 Dec; 18(1):1942712. PubMed ID: 34319865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Streptococcus pneumoniae as cause of acute otitis media (AOM) in Slovak children in the pneumococcal conjugate vaccine era (2008-2019).
    Macaj M; Perdochova L; Jakubikova J
    Vaccine; 2023 Jan; 41(2):452-459. PubMed ID: 36470684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of pneumococcal conjugate vaccines on otitis media from 2005 to 2013 in children aged ≤5 years: a retrospective cohort study in two Swedish regions.
    Edmondson-Jones M; Dibbern T; Hultberg M; Anell B; Medin E; Feng Y; Talarico C
    Hum Vaccin Immunother; 2021 Feb; 17(2):517-526. PubMed ID: 32574101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease among children in the United States between 2010 and 2019: An indirect cohort study.
    Andrejko KL; Gierke R; Rowlands JV; Rosen JB; Thomas A; Landis ZQ; Rosales M; Petit S; Schaffner W; Holtzman C; Barnes M; Farley MM; Harrison LH; McGee L; Chochua S; Verani JR; Cohen AL; Pilishvili T; Kobayashi M
    Vaccine; 2024 Jun; 42(16):3555-3563. PubMed ID: 38704263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. General health, otitis media, nasopharyngeal carriage and middle ear microbiology in Northern Territory Aboriginal children vaccinated during consecutive periods of 10-valent or 13-valent pneumococcal conjugate vaccines.
    Leach AJ; Wigger C; Beissbarth J; Woltring D; Andrews R; Chatfield MD; Smith-Vaughan H; Morris PS
    Int J Pediatr Otorhinolaryngol; 2016 Jul; 86():224-32. PubMed ID: 27260611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of routine childhood immunization with higher-valent pneumococcal conjugate vaccines on antimicrobial-resistant pneumococcal diseases and carriage: a systematic literature review.
    Tin Tin Htar M; van Den Biggelaar AHJ; Sings H; Ferreira G; Moffatt M; Hall-Murray C; Verstraeten T; Gessner BD; Schmitt HJ; Jodar L
    Expert Rev Vaccines; 2019 Oct; 18(10):1069-1089. PubMed ID: 31585049
    [No Abstract]   [Full Text] [Related]  

  • 18. Studying PCV impact on clinical presentation of otitis media helps to understand its pathogenesis.
    Ben-Shimol S; Givon-Lavi N; Leibovitz E; Greenberg D; Dagan R
    Vaccine; 2019 Jan; 37(1):1-6. PubMed ID: 30497832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiology of Streptococcus pneumoniae causing acute otitis media among children in Southern Catalonia throughout 2007-2013: Incidence, serotype distribution and vaccine's effectiveness.
    Ochoa-Gondar O; Figuerola-Massana E; Vila-Corcoles A; Aguirre CA; de Diego C; Satue E; Gomez F; Raga X;
    Int J Pediatr Otorhinolaryngol; 2015 Dec; 79(12):2104-8. PubMed ID: 26453272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. National impact of 13-valent pneumococcal conjugate vaccine on ambulatory care visits for otitis media in children under 5 years in the United States.
    Zhou X; de Luise C; Gaffney M; Burt CW; Scott DA; Gatto N; Center KJ
    Int J Pediatr Otorhinolaryngol; 2019 Apr; 119():96-102. PubMed ID: 30690309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.